Imugene tweeted 13 Mar
Another ground breaking publication from Imugene's City of Hope colleagues led by Professor Yuman Fong. Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer and is difficult to treat. The study shows that CF33-hNIS-ΔF14.5 (VAXinia) favourably modulates the tumour immune microenvironment in TNBC models making them responsive to immune checkpoint inhibitors and hence warrants further studies to determine the clinical applicability of this combination therapy. VAXinia will enter a Phase 1 clinical trial in 2020.
https://www.ncbi.nlm.nih.gov/pubmed...CRJgV3ji8tpsgq1r22wipvdNNE0uI6LE1YDF3fqZVJfLc
Imugene tweeted 13 Mar Another ground breaking publication from...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
0.002(4.35%) |
Mkt cap ! $357.0M | |||
| Open | High | Low | Value | Volume |
| 4.7¢ | 4.9¢ | 4.6¢ | $977.7K | 20.56M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 3232340 | 4.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.8¢ | 854027 | 4 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |